UniProtKB/Swiss-Prot P04150 : Variant p.Phe29Leu
Glucocorticoid receptor
Gene: NR3C1
Feedback ?
Variant information
Variant position:
29
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LB/B
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Phenylalanine (F) to Leucine (L) at position 29 (F29L, p.Phe29Leu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from large size and aromatic (F) to medium size and hydrophobic (L)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Polymorphism:
Carriers of the 22-Glu-Lys-23 allele are relatively more resistant to the effects of GCs with respect to the sensitivity of the adrenal feedback mechanism than non-carriers, resulting in a better metabolic health profile. Carriers have a better survival than non-carriers, as well as lower serum CRP levels. The 22-Glu-Lys-23 polymorphism is associated with a sex-specific, beneficial body composition at young-adult age, as well as greater muscle strength in males.
Additional information on the polymorphism described.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
29
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
777
The length of the canonical sequence.
Location on the sequence:
PGREENPSSVLAQERGDVMD
F YKTLRGGATVKVSASSPSLA
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human P--GREENPSSVL-AQERGDVMDF YKTLRGGATVKVSASSPSLA
Mouse P-PGRDEVPSSLL-GRGRGSVMDL YKTLRGGATVKVSASSP
Rat P-PGRDEVPGSLL-GQGRGSVMDF YKSLRGGATVKVSASSP
Pig P-PSREEIPSSVL-GRERAHVMDF YKSLRGGTPVKVSAASP
Rabbit P-PGREEVPSSVLRPAERGNVMDL YKTLRGGAPVRVPASSP
Xenopus laevis PSSGSPAVRGSPHYNDKPGNVIEF FGNYRGGVSVSVSASCP
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 777
Glucocorticoid receptor
Region
1 – 420
Modulating
Modified residue
23 – 23
Omega-N-methylarginine
Modified residue
45 – 45
Phosphoserine
Alternative sequence
1 – 335
Missing. In isoform Alpha-D3.
Alternative sequence
1 – 330
Missing. In isoform Alpha-D2.
Alternative sequence
1 – 315
Missing. In isoform Alpha-D1.
Alternative sequence
1 – 97
Missing. In isoform Alpha-C3.
Alternative sequence
1 – 89
Missing. In isoform Alpha-C2.
Alternative sequence
1 – 85
Missing. In isoform Alpha-C1.
Mutagenesis
27 – 27
M -> T. Abolishes expression of B-type isoforms.
Literature citations
Five missense variants in the amino-terminal domain of the glucocorticoid receptor: no association with puerperal psychosis or schizophrenia.
Feng J.; Zheng J.; Bennett W.P.; Heston L.L.; Jones I.R.; Craddock N.; Sommer S.S.;
Am. J. Med. Genet. 96:412-417(2000)
Cited for: VARIANTS LYS-23; LEU-29; PHE-112; ASN-233 AND SER-363;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.